Log in

NASDAQ:BVXV - BIONDVAX PHARMA/S Stock Price, Forecast & News

+0.26 (+2.92 %)
(As of 02/20/2020 02:59 AM ET)
Today's Range
Now: $9.15
50-Day Range
MA: $10.05
52-Week Range
Now: $9.15
Volume36,454 shs
Average Volume59,833 shs
Market Capitalization$59.80 million
P/E RatioN/A
Dividend YieldN/A
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BVXV



Sales & Book Value

Annual SalesN/A
Book Value($1.27) per share


Net Income$-23,410,000.00


Market Cap$59.80 million
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.

BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions

What is BIONDVAX PHARMA/S's stock symbol?

BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV."

How were BIONDVAX PHARMA/S's earnings last quarter?

BIONDVAX PHARMA/S (NASDAQ:BVXV) released its earnings results on Tuesday, November, 26th. The company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.54. View BIONDVAX PHARMA/S's Earnings History.

When is BIONDVAX PHARMA/S's next earnings date?

BIONDVAX PHARMA/S is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for BIONDVAX PHARMA/S.

Has BIONDVAX PHARMA/S been receiving favorable news coverage?

News headlines about BVXV stock have trended positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIONDVAX PHARMA/S earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for BIONDVAX PHARMA/S.

Are investors shorting BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 49,500 shares, an increase of 66.7% from the January 15th total of 29,700 shares. Based on an average daily volume of 31,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.8% of the shares of the company are short sold. View BIONDVAX PHARMA/S's Current Options Chain.

Who are some of BIONDVAX PHARMA/S's key competitors?

What other stocks do shareholders of BIONDVAX PHARMA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIONDVAX PHARMA/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), BIOLINERX LTD/S (BLRX), Agilent Technologies (A), Enterprise Products Partners (EPD), AT&T (T), NovaBay Pharmaceuticals (NBY) and Akari Therapeutics (AKTX).

Who are BIONDVAX PHARMA/S's key executives?

BIONDVAX PHARMA/S's management team includes the folowing people:
  • Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 57)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49)
  • Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 55)
  • Dr. Shimon Hassin, Chief Operating Officer
  • Mr. Elad Mark, Head of Site & Process Devel.


(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

Who are BIONDVAX PHARMA/S's major shareholders?

BIONDVAX PHARMA/S's stock is owned by many different of institutional and retail investors. Top institutional investors include Mariner LLC (0.87%) and Renaissance Technologies LLC (0.22%).

Which institutional investors are buying BIONDVAX PHARMA/S stock?

BVXV stock was acquired by a variety of institutional investors in the last quarter, including Mariner LLC and Renaissance Technologies LLC.

How do I buy shares of BIONDVAX PHARMA/S?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIONDVAX PHARMA/S's stock price today?

One share of BVXV stock can currently be purchased for approximately $9.15.

How big of a company is BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S has a market capitalization of $59.80 million. The company earns $-23,410,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe.View Additional Information About BIONDVAX PHARMA/S.

What is BIONDVAX PHARMA/S's official website?

The official website for BIONDVAX PHARMA/S is http://www.biondvax.com/.

How can I contact BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S's mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]

MarketBeat Community Rating for BIONDVAX PHARMA/S (NASDAQ BVXV)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about BIONDVAX PHARMA/S and other stocks. Vote "Outperform" if you believe BVXV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: Resistance Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel